Govt’s Policy Blueprint Will Lead to Soaring R&D Costs, More Early-Stage Projects: JPMA Drug Evaluation Chief

JPMA Drug Evaluation Committee Chairman Osamu Inagaki Drug makers’ R&D spending will balloon due to a new generic target and other measures included in the government’s 2015 economic and fiscal policy guidelines adopted in June, and together with the establishment...read more